Biomarker Test Market Business Opportunities, Market Challenges & Global Industry Analysis by 2025

According to Market Research Future (MRFR), the valuation of the global biomarker test is poised to escalate to USD 24,259 MN by 2025, registering 14.5 % CAGR throughout the assessment period (2019-2025). In 2018, the market valuation had reached USD 9,375, MN. Rising uptake of biomarker tests among most healthcare professionals to elucidate and support their clinical decision acts as a key driving force for the market. 

The biomarker test market is making significant strides over recent years. The market is witnessing an upward trajectory continually mainly due to the rising burden of pervasively growing rate of chronic diseases, and the technological advancements transpired in the biomarkers field. Moreover, the increasing demand for effective diagnostic processes and treatments are accelerating the growth of the market. 

Additional factors such as the increasing involvement of patients in personal healthcare, rising prevalence of genetic diseases, and growing potential for biomarkers in targeted therapies, substantiate the market growth. Also, augmenting demand for biomarker tests in next-generation sequencing and ultra-high-throughput sequencing technologies fosters the growth of the market. 

Conversely, the lack of knowledge about the possible applications and research and indications creating difficulties in their implementation, alongside the ethical and regulatory issues, impede the market growth. Also, inaccurate diagnosis of fatal diseases obstructs the growth of the market to an extent. Nevertheless, government grants and initiatives allotted to foster the R&D required in the biomarker's field would support the market throughout the review period. 

Biomarker Test Market   - Segmentation

The report has been segmented into three major dynamics.

By Application: Cancer, Infectious Diseases, Cardiovascular, Central Nervous System, and others

By End User: Pharma & Biotech Companies, Healthcare IT/Big Data Companies, Diagnostic Tool Companies, Clinical Laboratories, and others.

By Regions: Americas, Europe, Asia Pacific, Middle East & Africa, and Rest-of-the-World.

The application segment has been further bifurcated into cancer, infectious diseases, cardiovascular, central nervous system, and others. Among these, the cancer segment dominated the overall biomarker test market in 2018. The growth of the segment attributes to the increasing demand for rapid & accurate diagnostic tools and personalized medicines for the cancer treatment led by the growing prevalence of the disease.

Major Players:

Players leading the global biomarker test market include Novartis AG, F. Hoffmann-La Roche AG, Pfizer Inc., GE Healthcare, Medtronics plc. GlaxoSmithKline plc. And Quest Diagnostics, among others. 

Industry/Innovation/Related News:

February 19, 2020 ---- Cicero Diagnostics Inc. (the US), a women's healthcare diagnostic company, announced receiving the grant of USD 1 MN from the National Institutes of Health (NIH) to further research on markers for unexplained infertility, failed implantation and recurrent pregnancy loss. The grant, titled "SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity," will be used for further studies to Expand the acceptability and indications for BCL6/SIRT1 biomarker testing.

Article source: https://article-realm.com/article/Sports-Recreation/13509-Biomarker-Test-Market-Business-Opportunities-Market-Challenges-and-Global-Industry-Analysis-by-2025.html